Engineers created a rapid, equipment-free test strip that detects the heart failure peptide biomarker BNP at clinically useful levels in 30 minutes at room temperature.
30 minutes at room temperatureTime to detect BNP at clinically relevant levels without enzymes or lab equipment
What the researchers found
Researchers developed a new lateral flow test that detects brain natriuretic peptide (BNP) at clinically relevant levels (100 pg/mL threshold) in just 30 minutes at room temperature without requiring enzymes, cold storage, or laboratory equipment. The system uses two aptamers that simultaneously bind BNP, triggering an enzyme-free DNA amplification cascade that produces a visual result on a simple test strip.
Why it matters
BNP is the key blood biomarker for diagnosing heart failure, but current tests require expensive lab equipment and cold-stored antibodies. A rapid, room-temperature test strip could bring heart failure diagnosis to emergency rooms, ambulances, and clinics in resource-limited settings where lab-based immunoassays aren't available.
The numbers in context
Clinical rule-out threshold: 100 pg/mL (0.03 nM) · Detection time: 30 minutes · Room temperature operation · Enzyme-free amplification · Dual-aptamer system
How the study worked
Proof-of-concept laboratory study developing a lateral flow biosensor. Designed a dual-aptamer system where two DNA aptamers bind BNP simultaneously, releasing complementary DNA strands that trigger cyclic isothermal amplification. The amplified DNA products are detected on a lateral flow test strip providing visual readout. Tested with spiked samples at room temperature.
Who was studied
Laboratory proof-of-concept study (no human participants)
What this study cannot tell us
Proof-of-concept stage only — not yet validated with real human blood samples. Performance in clinical settings with complex biological matrices (blood, serum) is unknown. No comparison with existing commercial BNP immunoassays. Manufacturing scalability and cost not addressed. Interference from other blood components needs testing.
How to read the evidence
Preliminary evidence: proof-of-concept laboratory study demonstrating technical feasibility. Not yet validated with human clinical samples, so clinical utility remains unproven.
When this study was published
Published in 2026. Cutting-edge technology development. Clinical validation studies are planned but not yet completed.
The bigger picture
Point-of-care diagnostics are transforming how peptide biomarkers are used in medicine. BNP testing is critical for heart failure management, but access barriers in low-resource settings mean many patients go undiagnosed. This work represents a broader trend of replacing expensive antibody-based tests with aptamer technology — synthetic DNA molecules that can bind specific targets with antibody-like precision but without needing refrigeration. If validated clinically, this could democratize heart failure diagnosis globally.
Questions still open
- Will this test maintain its sensitivity and specificity when used with actual patient blood samples?
- How does the cost of manufacturing this aptamer-based test compare to existing antibody-based BNP immunoassays?
- Could the same dual-aptamer lateral flow approach be adapted for other peptide biomarkers like NT-proBNP or troponin?
Common questions
What is BNP and why is it important for heart failure?
How is this test different from existing BNP tests?
Read the original research
Lateral flow biosensors for low abundance detection of brain natriuretic peptide with enzyme-free amplification.
Lab on a chip, 26(3), 627-634
Citation
Zhang, Menghan; Xu, Tao; Jajesniak, Pawel; Core, Giulia; Zeng, Zhuoer; Shalaby, Maha Mansour Mohamed; Reboud, Julien; Cooper, Jonathan M. (2026). Lateral flow biosensors for low abundance detection of brain natriuretic peptide with enzyme-free amplification.. Lab on a chip, 26(3), 627-634. https://doi.org/10.1039/d5lc00793c